MC
MRNS

Menta Capital’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Menta Capital’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,653
Closed -$112K – 1027
2015
Q4 		$112K Sell
3,653
-1,487
-29% -$43.6K 0.01% 816
2015
Q3 		$171K Buy
+5,140
New +$290K 0.03% 644

Other funds holding MRNS

CPV
Canaan Partners VII Westport, Connecticut $32.3M AUM 154.97% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Menta Capital's MRNS Position: Q1 2016 in Review

Menta Capital sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2016, closing a stake of 3,653 shares — an estimated $112K sold.

Menta Capital first reported a position in MRNS in Q3 2015 and held it in 2 quarters. The position peaked at $171K in Q3 2015. 31 funds tracked by Wall St. Rank hold MRNS as of Q1 2016.

  • Menta Capital reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2016 after selling out during the quarter.
  • Menta Capital sold 3,653 Marinus Pharmaceuticals, Inc shares in Q1 2016, an estimated $112K.
  • Menta Capital first reported a position in Marinus Pharmaceuticals, Inc in Q3 2015 and held it in 2 quarters.
  • Menta Capital's Marinus Pharmaceuticals, Inc position peaked at $171K in Q3 2015.
  • 31 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2016.

Based on Menta Capital's 13F filing for Q1 2016, filed 11 May 2016.